Firefly Neuroscience Inc. (AIFF) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Firefly Neuroscience Inc. (AIFF) slipped -1.90% to $1.03, trading at 16% of its 52-week range ($0.62 – $3.15). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
– Firefly’s AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity – – With over 3,000 Versus headsets shipped, the platform generates commer
Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AIFF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AIFF. Explore sector supply chains on /butterfly.
Across 714 tracked Technology securities in the Roarable RQD universe, Firefly Neuroscience Inc. (AIFF) ranks #598 by composite RQD confidence (37/100, grade D-) and #622 by equity capitalization ($16.2M). Within this direct 5-issuer industry benchmark cohort, AIFF leads on earnings valuation at N/A trailing P/E, while INLX leads on capital efficiency and profitability with -12.4% ROIC and 66.0% gross margin. VIDA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with AIFF at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AIFF
ACTIVE
Firefly Neuroscience Inc. | D- | 37/100 | — | 56.5% | -35.0% | -1.90% | $16.2M | Benchmark Subject |
| IDAI T Stamp Inc. (Class A) | D | 50/100 | — | — | -35.0% | +4.00% | $16.3M | /idai-vs-aiff → |
| VIDA VIDA Global Inc. (Class A) | D+ | 56/100 | — | — | — | -2.74% | $15.6M | /vida-vs-aiff → |
| SAGT SAGTEC GLOBAL LIMITED (Class A) | D+ | 55/100 | — | — | — | -5.66% | $14.1M | /sagt-vs-aiff → |
| INLX Intellinetics Inc. | D- | 39/100 | — | 66.0% | -12.4% | -1.89% | $18.7M | /inlx-vs-aiff → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Firefly Neuroscience Inc. (AIFF) reported GAAP revenue of $1.1M (+957.4% vs. FY2024 revenue of $108.0K , and +129.3% cumulative change since FY2023) , GAAP net income of -$19.9M, operating cash flow of -$8.2M, and free cash flow of -$8.2M (-33.1% YoY). On the balance sheet, AIFF closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.1M | -$19.9M | -$8.2M | -$8.2M | $10.5M | — |
| FY2024 (FY) | 2024-12-31 | $108.0K | -$10.5M | -$6.2M | -$6.2M | $4.6M | — |
| FY2023 (FY) | 2023-12-31 | $498.0K | -$2.6M | -$2.2M | -$2.2M | — | — |
As of 2026-11-01, Firefly Neuroscience Inc. (NASDAQ: AIFF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.03 (-1.90% 1D, market cap $16.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 714 tracked Technology issuers, AIFF ranks #598 in composite RQD confidence.
Within the Technology sector (Computer Software: Prepackaged Software), AIFF carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, IDAI (T Stamp Inc. (Class A)) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and VIDA (VIDA Global Inc. (Class A)) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $15.6M). Among the 5-stock peer group, AIFF leads on earnings multiple (N/A) while INLX leads on capital efficiency (-12.4% ROIC).
Per AIFF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000803578), Firefly Neuroscience Inc. generated $1.1M in revenue (+957.4% YoY), -$19.9M in net income, and -$8.2M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Technology with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AIFF last traded at $1.03 (-1.90% on volume of 71,088 shares), positioning the stock -11.21% below its 50-day simple moving average ($1.16) and -24.82% below its 200-day simple moving average ($1.37). Across its 52-week range of $0.62 to $3.15, AIFF sits at the 16.2% percentile with a 14-day RSI of 42.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.16).
Why AIFF Stock slipped -1.90% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.